EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Horizon Pharma plc

NEW YORK--(BUSINESS WIRE)--

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Horizon Pharma plc HZNP resulting from allegations that Horizon Pharma may have issued materially misleading business information to the investing public.

On October 19, 2015, The New York Times published an article reporting that various drug manufacturers, including Horizon Pharma, have used specialty pharmacies "to circumvent efforts of insurers and pharmacists to switch patients to generic components, or even to the over-the-counter versions," and that by convincing doctors to submit prescriptions to affiliated mail-order specialty pharmacies, Horizon Pharma was able to charge inflated prescription prices. On this news, shares of Horizon Pharma fell $3.81 per share or over 19% to close at $15.26 per share on October 20, 2015, damaging investors.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Horizon Pharma investors. If you purchased shares of Horizon Pharma on or before October 19, 2015, please visit the firm's website at http://rosenlegal.com/cases-782.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151111006571/en/